Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name SMO D473H
Gene Variant Detail

SMO D473H (no effect - predicted)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
SMO D473H basal cell carcinoma resistant Sonidegib Phase I Actionable In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473H with resistance to Erivedge (vismodegib) (PMID: 26546616). 26546616
SMO D473H Advanced Solid Tumor predicted - sensitive TAK-441 Preclinical Actionable In a preclinical study, TAK-441 inhibited Gli-reporter activation in cells transfected with SMO D473H in culture (PMID: 24291104). 24291104
SMO D473H Advanced Solid Tumor sensitive Taladegib Preclinical Actionable In a preclinical study, LY2940680, inhibited the activity of SMO D473H, which is a mutant that confers resistance to the treatment of vismodegib (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819). detail...
Clinical Trial Phase Therapies Title Recruitment Status